After over two years of online meetings, the Hypo-RESOLVE consortium was finally able to meet in person again. Partner Abbott kindly hosted the consortium on their premises in Wiesbaden/ Delkenheim from 28 to 29 November 2022. After a warm welcome by Dr Alexander Seiboldt, host of the meeting, Coordinator Prof Bastiaan de Galan from Stichting Radboud Universitair Medisch Centrum and the Project Leader Dr Matthias Müllenborn from Novo Nordisk addressed the plenum. The Patient Advisory Committee (PAC) session following the welcome notes once again stressed the invaluable support the PAC offers to the various work packages and the project as such. The PAC members and the Work Package Leaders agreed that for the final year in Hypo-RESOLVE the cooperation is of utmost importance and will be intensified. The remainder of the first day was dedicated to the presentations of each work package’s progress and achieved results during the past year, as well as providing an outlook on the remaining activities to reach the project’s objectives until its end on 31 October 2023. A dedicated session was reserved for communication, dissemination, exploitation and particularly for the sustainability of the project’s outcomes. The General Assembly meeting, which was chaired by Project Leader Novo Nordisk supported by Project Management Partner EURICE and which focused on consortium management and contractual updates, closed the day. In the first session on day 2, the IHI Scientific Project Officer for Hypo-RESOLVE, Klelia Salpea, gave an informative presentation on the new IHI structure, and particularly stressed the opportunities and help the EU offers in dissemination of results. A very important aspect of her presentation was the sustainability of the project’s results, especially by submitting proposals to future calls for follow-up funding. Three sessions focussing on specific topics of importance to the consortium rounded off the scientific discussions. The consortium was particularly pleased to welcome representatives from the Hypo-RESOLVE Ethics Advisory Board and the Strategic Advisory Board, who followed the meeting online and addressed the consortium in a short statement, stressing the impressive progress and promising results that were obtained over the past year, despite the delays and slow-down due to COVID. The consortium will meet again for its final progress meeting near the end of the project.